Merit Medical Systems Inc

Merit Medical Systems Inc(MMSI)股票分析

$89.960

+0.765 (+0.85%)收盤時

Loading chart…
最高
90.740
開盤
88.850
成交量加權均價
89.85
成交量
580.99K
市值
4.85B
最低
88.850
成交金額
52.20M
企業價值/稅息折舊攤銷前利潤(TTM)
14.73

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

AI 分析 of Merit Medical Systems Inc (MMSI)

買進

Merit Medical Systems Inc (MMSI) is a good buy right now due to its strong recent performance, including a 10% year-over-year revenue growth in Q2 2026, and a current price of $89.2, which is below the average analyst price target of $97. Additionally, the company has a forward P/E ratio of 18.94, indicating potential for growth relative to its earnings. However, a risk to consider is the significant insider selling, which has increased by 1341.20% over the last month, suggesting potential concerns from insiders about the stock's future performance.

分析師評級(9)

上檔空間 +16.31%
買進
8 買進
1 持有
0 賣出
目前: 89.96
最低
90.00
平均
104.63
最高
122.00

BofA

2026-08-12

目標價

$97

中性

Canaccord

2026-08-03

目標價

$94

買進

BTIG

2026-07-31

目標價

$105

買進

Raymond James

2026-07-31

目標價

$100

優於大盤

Barrington

2026-07-31

目標價

$114

優於大盤

估值指標

Merit Medical Systems Inc(MMSI)目前預期本益比為 18.94,5 年平均預期本益比為 24.12。

預期本益比

低估
5 年均值 P/E
24.12
目前P/E
18.94
高估
27.48
低估
20.76

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
16.85
目前EV/EBITDA
14.73
高估
19.07
低估
14.64

預期股價營收比

合理
5 年均值 P/S
3.27
目前P/S
3.07
高估
3.75
低估
2.79

Alphio AI 對 MMSI 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MMSI

$115.59

情境價格

基

基準

基準 · 50%MMSI

$110.74

情境價格

悲

悲觀

悲觀 · 25%MMSI

$87.37

情境價格

持有 MMSI 的大戶

M

Maverick Capital, Ltd.

+ 持有MMSI

+4.02%

3個月報酬率

J

J. Goldman & Co., L.P.

+ 持有MMSI

+2.90%

3個月報酬率

W

Westwood Management Corp.

+ 持有MMSI

+0.25%

3個月報酬率

事件時間軸

2026-07-30 (ET)

20:30:00

Amazon Earnings Beat Expectations, Stock Rises Nearly 10%

16:30:00

Merit Raises FY26 Revenue Outlook to $1.631B-$1.643B

2026-04-30 (ET)

16:21:00

Company Narrows FY26 Revenue View to $1.612B-$1.634B

16:21:00

Merit Q1 Revenue Exceeds Expectations at $381.9M

資訊

MMSI 常見問題 —— 由 Alphio AI 解答

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Merit Medical Systems Inc (MMSI) is a good buy right now due to its strong recent performance, including a 10% year-over-year revenue growth in Q2 2026, and a current price of $89.2, which is below the average analyst price target of $97. Additionally, the company has a forward P/E ratio of 18.94, indicating potential for growth relative to its earnings. However, a risk to consider is the significant insider selling, which has increased by 1341.20% over the last month, suggesting potential concerns from insiders about the stock's future performance.

9 analysts cover MMSI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 104.63.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易